Alnylam Pharmaceuticals Inc
ALNY.O- Latest Trade
- trading higher147.5USD
- Change
- 1.2
- % Change
0.82%Positive
- Day Range
- 144.34 - 148.25
- 52-Week Range
- 117.58 - 212.00
As of Jun 25 2022. Values delayed up to 15 minutes
- Previous Close
- 146.30
- Open
- 147.68
- Volume
- 1,629,326.00
- 3 Month Average Trading Volume
- 18.09
- Shares Out (Mil)
- 120.81
- Market Cap
- 17,675.02
- Forward P/E --
- Dividend Yield
- -99,999.99
Key Statistics
2 mean rating - 23 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 20.09
- Price To Book (Quarterly)
- 44.03
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 168.69
- Long Term Debt/Equity (Quarterly)
- 168.69
- Return On Investment (TTM)
- -31.96
- Return On Equity (TTM)
- -26.70
2021 (millions USD)
About Alnylam Pharmaceuticals Inc
Company Information
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based medicines include ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1. Leqvio is used for the treatment of adults with hypercholesterolemia.
Executive Leadership
- Michael W. Bonney
- Executive Chairman of the Board
- Akshay K. Vaishnaw
- President
- Yvonne L. Greenstreet
- Chief Executive Officer, Director
- Jeffrey V. Poulton
- Chief Financial Officer, Executive Vice President
- Indrani L. Franchini
- Executive Vice President, Chief Legal Officer and Secretary
- Pushkal P. Garg
- Chief Medical Officer, Executive Vice President, Development and Medical Affairs
- Tolga Tanguler
- Chief Commercial Officer
- Amy W. Schulman
- Lead Independent Director
- Dennis A. Ausiello
- Independent Director
- Olivier Brandicourt
- Independent Director
- Marsha H. Fanucci
- Independent Director
- Margaret A. Hamburg
- Independent Director
- David E. I. Pyott
- Independent Director
- Colleen F. Reitan
- Independent Director
- Phillip A. Sharp
- Independent Director
Latest News
- MarketsSwiss stocks - Factors to watch on January 6
The Swiss blue-chip SMI was seen opening 1.3% lower at 12,741 points on Thursday, according to premarket indications from bank Julius Baer .
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,825.70 | -- |
| Copper | 693.65 | 0.33%Negative |
| Brent Crude Oil | 113.12 | -- |
| CBOT Soybeans | 1,609.00 | 0.99%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,911.74 | 3.06%Positive |
| Euro STOXX 50 | 3,533.17 | 2.82%Positive |
| FTSE 100 | 7,208.81 | 2.68%Positive |
| Nikkei 225 | 26,491.97 | 1.23%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes